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Behc ¸et’s disease is a multisystem inﬂammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis,
and skin lesions. The cause of Behc ¸et’s disease remains unknown, but epidemiologic ﬁndings suggest that an autoimmune
process is triggered by an environmental agent in a genetically predisposed individual. An infectious agent could operate through
molecular mimicry, and subsequently the disease could be perpetuated by an abnormal immune response to an autoantigen in
the absence of ongoing infection. Potentia bacterial are Saccharomyces cerevisiae,m y c o b a c t e r i a ,Borrelia burgdorferi, Helicobacter
pylori, Escherichia coli, Staphylococcus aureus,a n dMycoplasma fermentans, but the most commonly investigated microorganism is
Streptococcus sanguinis. The relationship between streptococcal infections and Behc ¸et’s disease is suggested by clinical observations
that an unhygienic oral condition is frequently noted in the oral cavity of Behc ¸et’s disease patients. Several viral agents, including
herpes simplex virus-1, hepatitis C virus, parvovirus B19, cytomegalovirus, Epstein-Barr virus and varicella zoster virus, may also
have some role.
1.Introduction
Behc ¸et’s disease is a multisystem inﬂammatory disorder
characterized by recurrent oral aphthous ulcers, genital
ulcers, uveitis, and skin lesions and generally presents with
remissions and exacerbations. It can frequently involve the
joints, gastrointestinal tract, and central nervous system
[1, 2].
2. Epidemiology
Behc ¸et’s disease is most prevalent along the “Silk Road,” an
ancient trading route between the Mediterranean and East
Asia, where it is a major cause of morbidity. In Turkey,
the country with the highest incidence of the disease, the
prevalence is estimated to be between 110 and 420 per
100.000, whereas that in Japan is 13–20 per 100.000, and
the prevalence in the UK and USA is estimated at 1-2 per
100.000. The typical age of onset is in the third or fourth
decade of life and the male-to-female ratio varies with ethnic
origin [1, 3, 4].
The study of migrant populations led to interesting
epidemiological ﬁndings. Individuals from endemic areas
who have immigrated to areas with low prevalence of the
disease have an intermediate risk for developing the disease,
which points that environment has some role in Behc ¸et’s
disease. Turkish individuals who have emigrated to Germany
have a signiﬁcantly lower risk of disease than individuals of
Turkish origin living in Turkey, although their risk remains
higher than that of the native German population. Similarly,
the disease is virtually unknown in Japanese immigrants to
Hawaii, mainland USA, or South America despite a high
prevalence in Japan [5, 6].
3. Pathogenesis
The cause of Behc ¸et’s disease remains unknown, but
epidemiologic ﬁndings suggest that an autoimmune process
istriggeredbyaninfectiousorenvironmentalagent(possibly
local to a geographic region) in a genetically predisposed
individual [7, 8]. Whatever the stimulus is, the target
tissue seems to be the small blood vessels, with various
consequences of either vasculitis and/or thrombosis in many
organ systems [9].
The genetic susceptibility is strongly associated with the
presenceoftheHLA-B51allele,withastrongerassociationin2 Pathology Research International
Turkish and Japanese patients in comparison to Caucasians.
The unusual geographic distribution of Behc ¸et’s disease and
its close association with HLA-B51 may be the strongest
indicator that certain genes are directly responsible for
Behc ¸et’s disease or of indirectly promoting the characteris-
tics of the underlying inﬂammatory changes. Other genes
located outside the HLA region have been also proposed,
including genes of coagulation factor V, intercellular adhe-
sion molecule-1 (ICAM-1), and endothelial nitric oxide
synthetase [10–12].
As is the case of other autoimmune diseases, there is
interest in an infectious etiology. Although there is no
information supporting the role of a single microorganism
as the speciﬁc cause, a problem with dysregulation in
innate immunity, with an altered response to more than
one infectious agent, is a generally accepted theory. An
infectious agent could operate through molecular mimicry.
This mimicked interaction or false signalling could attract
the inﬂammatory cells into the ﬁeld of action, and this may
in turn result in vasculitis. Subsequently, the disease could
b ep e r p e t u a t e db ya na b n o r m a li m m u n er e s p o n s et oa n
autoantigen in the absence of ongoing infection [13].
A viral cause was ﬁrst postulated by Behc ¸et in 1937
[14]. Evidence of ongoing infection with a variety of viral
agentshasbeensought.However,oftenthereisonlyahistory
of previous infection and/or seropositivity [2]. Although
herpetiform ulcers are unusual, herpes simplex virus-1
(HSV-1) is currently the most common virus associated with
Behc ¸et’s disease. HSV DNA and serum antibodies against the
virushavebeenfoundinahigherproportionofpatientswith
Behc ¸et’s disease than in controls, and circulating immune
complexes with the HSV-1 antigen have been reported.
HSV DNA has been demonstrated in the genital and
intestinal ulcers, but not in oral ulcers. However, anti-HSV
immunity is also common in normal subjects, and results
about therapeutic eﬀects of antiviral treatment in Behc ¸et’s
disease are scarce and controversial [15, 16]. Several other
viral agents, including hepatitis C virus, parvovirus B19,
cytomegalovirus, Epstein-Barr virus, and varicella zoster
virus, may also have some role [17–21].
Potential bacteria are a variety of streptococcal antigens,
Saccharomyces cerevisiae,m y c o b a c t e r i a ,Borrelia burgdorferi,
Helicobacter pylori, Escherichia coli, Staphylococcus aureus,
Mycoplasma fermentans [22–27]. The infectious model is
also supported by observations that oral ulcers precede the
establishment of disease by months or years and disease
relapses are frequent. Thus, oral microbial ﬂora have long
been implicated in the pathogenesis. The most commonly
investigated microorganism is Streptococcus. The relation-
ship between streptococcal infections and Behc ¸et’s disease
is suggested by clinical observations that an unhygienic
oral condition including periodontitis, decayed teeth, and
chronic tonsillitis is frequently noted in the oral cavity
of Bechet’s disease patients [28]. It is not clear that the
predisposition of the patients is correlated with streptococcal
infection, but the uncommon oral Streptococcus sanguinis
serotypes (called KTH-1) and antibodies against the bacteria
are signiﬁcantly increased in the oral ﬂora and serum,
respectively, of patients with the disease compared with
healthy controls [29]. The patients show strong delayed-type
cutaneous hypersensitivity reactions against streptococcal
antigens in skin tests and sometimes Behc ¸et’s disease symp-
toms were provoked by skin injection of the antigens [30].
The new criteria included hypersensitivity skin reactions
against streptococci in the diagnosis as one of the references
and the levels of disease severity of Behc ¸et’s disease patients
[31]. S. sanguinis antigens share a sequence of amino acids
with one of the protein classes of the cellular membranes
called heat shock proteins (HSPs), which are expressed
above the cellular membrane in response to physiological
shocks and microbial stimulus [12]. Thus, HSPs are possible
candidate antigen for Behc ¸et’s disease. Particularly, the
peptides of 65kDa (HSP-65) derived from the bacteria show
considerable homology with those of the human 60kDa
(HSP-60). Moreover, mycobacterial and human HSPs have
over 50% in sequence homology [32]. Studies have shown
that S. sanguis and HSP 60/65kDa activate γδTc e l l si n
Behc ¸et’s disease patients but not controls. It is suggested
that, following the bacterial stimulus, mucous cells express
HSPs which are antigenic and reactive antimucous T cells
in susceptible individuals (molecular mimicry model) [30].
As for the most other autoimmune disorders, the Th1-type
polarization is predominant in Behc ¸et’s disease [7]. γδT
lymphocytes have a role in the immune response to infec-
tions and in autoimmunity by recognizing bacteria-derived
and autologous antigens. Patients with Behc ¸et’s disease have
increased numbers of activated γδT cells (in circulation and
in mucosal lesions), which produce inﬂammatory cytokines,
including IFN-γ,T N F - α,a n dI L - 8 .C u l t u r eo fγδTl y m p h o -
cytes from Behc ¸et’s disease patients proliferates in response
to mycobacterial HSP-derived peptides and in response
to products from microorganisms in oral ulcers [11, 33].
Complex interactions between T cells, antigen presenting
cells, (APCs) and neutrophils are involved in the immune
pathogenesis of Behc ¸et’s disease. Neutrophils are hyperactive
in Behc ¸et’s disease, with increased chemotaxis, phagocytosis,
superoxide production and myeloperoxidase expression and
produceseveralcytokines[34].Behc ¸et’sdiseaselesionsmight
be induced with vascular reaction or lymphocytic vasculitis
as the immunological reaction by the APCs expressing the S.
sanguinis antigens [30]. Moreover, the amino acid sequence
ofthepeptidesofBes-1,agenederivedfromoralS.sanguinis,
shows more than 60% similarity to the human intraocular
ganglion peptide, Brn-3b. These results suggest that Bes-1
might be an inducer for the retinal and neural involvement
possible in Behc ¸et’s disease patients [35].
Pustularskinlesionsareoftennotsterileandmaycontain
Staphylococcus aureus and Prevotella species. Whether these
pustules are secondarily infected or whether the infections
play a pathogenic role in the development of pustular lesions
remains to be determined [36].
Anti-S. cerevisiae antibodies (ASCAs) may be especially
common in intestinal Bec ¸het’s disease and are also increased
inhealthyrelativesofpatients,accordingtothestudybyChoi
et al. who evaluated whether ASCA expression is associated
with clinical ﬁndings at diagnosis and the clinical course
of intestinal Behc ¸et’s disease and found that the ASCA-
positive rate was 44.3% in intestinal Behc ¸et’s disease but wasPathology Research International 3
not related to clinical ﬁndings at diagnosis and cumulative
relapse rates [37].
Mycoplasmasareknowntoexhibitmolecularmimicryto
eukaryotic structures that may modulate immune responses
[27, 38].
4. Therapeutic Implications
Antiseptic agents and antibiotics are used to control micro-
bial contamination and secondary infection [39]. Chlorhexi-
dinegelandtriclosanhavebeenshowntoreducethenumber,
pain severity, and duration of aphthous ulcers [40, 41].
Antibiotics, especially tetracycline, has been widely used
in oral ulcers of Behc ¸et’s disease for years. Tetracycline
mouthwash decreases pain severity and duration of oral
ulcers. Minocycline mouthwashes as compared to topical
tetracycline rinses resulted in signiﬁcantly improved pain
control, by reducing the severity and duration of pain [42].
Minocyclinereducesnotonlythegrowthoforalstreptococci,
butalsosuppressesinterleukinsproductionfromTcells[43].
Theeﬀectofpenicillinonmucocutaneouslesionsandarthri-
tis has been examined in two diﬀerent studies, and it was
found that prophylactic penicillin treatment reduced both
the mucocutaneous lesions and the arthritis episodes. Other
studies also showed that combination therapy, 1200000
units of benzathine-penicillin injected monthly plus 1mg
of oral colchicine daily for 4 months, was eﬀective to
suppress Behc ¸et’s disease symptoms, compared to colchicine
monotherapy [44–46].
Acyclovir is not eﬀective in the treatment of oral and
genital ulceration [47].
5. Conclusion
The role of microorganisms in the pathogenesis of Behc ¸et’s
disease has long been investigated, and there are ample
data on several microorganisms. However, none of these
infectious agents have been proved to cause Behc ¸et’s disease.
Thus, a complex immune response might be generated to a
groupofmicroorganismsthatsharecommonantigensrather
than to an infection due to a speciﬁc single microorganism.
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